Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Episode 3 - American Heart Association’s 2018 Cholesterol Guidelines and the Implications for Type 2 Diabetes

Episode 3 - American Heart Association’s 2018 Cholesterol Guidelines and the Implications for Type 2 Diabetes

FromKnow Diabetes by Heart™ Professional Education Podcast Series


Episode 3 - American Heart Association’s 2018 Cholesterol Guidelines and the Implications for Type 2 Diabetes

FromKnow Diabetes by Heart™ Professional Education Podcast Series

ratings:
Length:
29 minutes
Released:
Jan 10, 2019
Format:
Podcast episode

Description

For people with diabetes, blood glucose isn’t the only important factor to track. New guidelines suggest the more than 110 million U.S. adults with diabetes or prediabetes should also manage their cholesterol as well as their blood glucose. Drs. Ronald Goldberg and Robert Eckel discuss the new American Heart Association’s 2018 Cholesterol Guidelines, released in November 2018, and the implications for type 2 diabetes along with pharmacotherapy and lifestyle interventions.
Released:
Jan 10, 2019
Format:
Podcast episode

Titles in the series (33)

The American Heart Association and the American Diabetes Association are excited to announce a new podcast series for healthcare professionals. Know Diabetes by Heart™ Professional Education Podcast Series focuses on the link between cardiovascular disease (CVD) and type 2 diabetes (T2D). The series will consist of relevant cutting-edge topics such as up-to-date standards of care, guidelines and their implications for T2D and CVD, and approaches to shared decision making—among others. The American Heart Association’s and the American Diabetes Association's Know Diabetes by Heart Professional Education™ Podcast Series is brought to you by founding sponsors, Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance and Novo Nordisk, and national sponsors, Sanofi, AstraZeneca, and Bayer.